Dr. DiMarchi contributions in peptide & protein sciences consists of three decades of work in academia, the pharmaceutical industry and biotechnology companies. He is co-founder of Ambrx, Marcadia, Assembly, Calibrium and MB2 biotechnology companies. He has served as a scientific advisor to multiple pharmaceutical companies and three venture funds; 5AM, TMP, and Twilight.
Dr. DiMarchi is a Vice President at Novo Nordisk Research Laboratories and a former Group Vice President at Eli Lilly and Company where for more than two decades he provided leadership in biotechnology, endocrine research and product development. He is readily recognized for discovery and development of rDNA-derived Humalog® (LisPro-human insulin), rGlucagon®, and Forteo®. His academic research has helped to broaden the understanding of glucagon physiology while championing the discovery of single molecule mixed agonists for the treatment of diabetes and obesity.
Dr. DiMarchi is the recipient of numerous awards including the AAPS Career Achievement Award in Biotechnology, the Carothers Award for Excellence in Polymer Sciences, the Merrifield Award for Career Contributions in Peptide Sciences, the Meienhofer Award, the Max Bergmann Medaille, Erwin Schrödinger-Preis, and the Alfred Burger Career Award in Medicinal Chemistry. He is a member of the National Inventors Hall of Fame and the National Academy of Medicine, and identified as a top-five translation researcher by Nature Biotechnology for the years 2014 and 2015.
« Go Back